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Objectives: The aim of this study is to assess the efficacy of the use of pre-exposure prophylaxis (PrEP) with
hydroxychloroquine against placebo in healthcare workers with high risk of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection in reducing their risk of coronavirus disease 2019 (COVID-19) disease during
an epidemic period.
As secondary objectives, we would like to: i) assess the efficacy of the use of PrEP with hydroxychloroquine against
placebo in healthcare workers with high risk of SARS-CoV-2 infection in reducing their risk of exposure to SARS-CoV-2
(defined by seroconversion) during an epidemic period, ii) evaluate the safety of PrEP with hydroxychloroquine in
adults, iii) describe the incidence of SARS-CoV-2 infection among healthcare workers at high risk of SARS-CoV-2
infection, iv) identify clinical, analytical and microbiological predictors of COVID-19 among healthcare workers at high
risk of SARS-CoV-2 infection, v) set up a repository of serum samples obtained from healthcare workers at high risk of
SARS-CoV-2 infection for future research on blood markers to predict SARS-CoV-2 infection.
Trial design: Multicentre double-blind parallel design (ratio 1:1) randomized controlled clinical trial.
Participants: Approximately 440 healthcare workers of four Spanish hospitals (Hospital Clínic of Barcelona, Hospital de la
Santa Creu i Sant Pau of Barcelona, Hospital Plató of Barcelona, Hospital General de Granollers, Barcelona) will be recruited.
Participants are considered to be at high-risk of SARS-CoV-2 infection due to their frequent contact with suspected and
confirmed cases of COVID-19.
For eligibility, healthcare workers with 18 years old or older working at least 3 days a week in a hospital with both
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negative SARS-CoV-2 polymerase chain reaction (PCR) assays and serological COVID-19 rapid diagnostic tests (RDT) are
invited to participate. Participants with any of the following conditions are excluded: pregnancy, breastfeeding, ongoing
antiviral, antiretroviral or corticosteroids treatment, chloroquine or hydroxychloroquine uptake the last month or any
contraindication to hydroxychloroquine treatment.
Intervention and comparator: Eligible participants will be allocated to one of the two study groups:
 Intervention group (PrEP): participants will receive the standard of care and will take 400mg of hydroxychloroquine
(2 tablets of 200 mg per Dolquine® tablet) daily the first four consecutive days, followed by 400 mg weekly for a
period of 6 months.
 Control group: participants will receive placebo tablets with identical physical appearance to hydroxychloroquine
200 mg (Dolquine®) tablets following the same treatment schedule of the intervention group.
Both groups will be encouraged to use the personal protection equipment (PPE) for COVID-19 prevention according to
current hospital guidelines.
Main outcomes: The primary endpoint will be the number of confirmed cases of a COVID-19 (defined by a positive PCR
for SARS-CoV-2 or symptoms compatible with COVID-19 with seroconversion) in the PrEP group compared to the placebo
group at any time during the 6 months of the follow-up in healthcare workers with negative SARS-CoV-2 PCR and
serology at day 0.
As secondary endpoints, we will obtain: i) the SARS-CoV-2 seroconversion in the PrEP group compared to placebo during
the 6 months of follow-up in healthcare workers with negative serology at day 0; ii) the occurrence of any adverse event
related with hydroxychloroquine treatment; iii) the incidence of SARS-CoV-2 infection and COVID-19 among healthcare
workers in the non-PrEP group, among the total of healthcare workers included in the non-PrEP group during the study
period; iv) the risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19; v) a
repository of serum samples obtained from healthcare workers confirmed COVID-19 cases for future research on blood
markers to predict SARS-CoV-2 infection.
Randomisation: Participants meeting all eligibility requirements will be allocated to one of the two study arms (PrEP with
hydroxychloroquine or non-PrEP control group) in a 1:1 ratio using simple randomisation with computer generated
random numbers.
Blinding (masking): Participants, doctors and nurses caring for participants, and investigators assessing the outcomes will
be blinded to group assignment.
Numbers to be randomised (sample size): Each intervention group will have 220 participants, giving a total of 440
participants.
Trial Status: The current protocol version is 1.5, 2nd of June 2020. Two hundred and seventy-fiveparticipants were
recruited and completed first month follow-up until date. The estimated sample size could not be reached yet due to the
declining national epidemic curve. Thus, 275 is the total number of participants included until date. The study has been
suspended (26th of June) until new epidemic curve occurs.
Trial registration: This trial was registered on April 2nd 2020 at clinicaltrials.gov with the number NCT04331834.
Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the
interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a
summary of the key elements of the full protocol.
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